Table 1 Distribution of baseline biomarker concentrations by treatment group in the STRATOS 1 all-comers population (full analysis set)
Biomarker | Combined placeboa(N = 400) | Tralo 300 mg Q2W(N = 398) | Tralo 300 mg Q4W(N = 404) | |
|---|---|---|---|---|
FeNO, ppb | n | 398 | 395 | 397 |
Mean (SD) | 29.6 (28.2) | 30.5 (30.6) | 29.2 (29.0) | |
Median (range) | 20.2 (2.3–189.9) | 20.3 (0.0–244.0) | 20.4 (0.0–201.8) | |
Periostin, ng/ml | n | 398 | 397 | 403 |
Mean (SD) | 25.4 (11.8) | 26.3 (12.7) | 26.0 (11.1) | |
Median (range) | 22.8 (7.6–83.4) | 23.0 (9.5–91.6) | 23.3 (8.7–78.8) | |
Eosinophils, cells/μl | n | 393 | 393 | 395 |
Mean (SD) | 254 (204) | 308 (468) | 296 (381) | |
Median (range) | 200 (20–2,020) | 210 (0–7,510) | 200 (0–5,880) | |
DPP-4, ng/ml | n | 399 | 397 | 404 |
Mean (SD) | 262.0 (75.6) | 264.0 (91.8) | 267.0 (77.0) | |
Median (range) | 251.0 (92.0–617.0) | 246.0 (87.0–766.0) | 254.0 (103.0–721.0) | |
IgE, IU/ml | n | 395 | 392 | 399 |
Mean (SD) | 432.0 (786.2) | 429.2 (929.0) | 440.4 (974.2) | |
Median (range) | 165.9 (2.1–5,347) | 141.8 (1.4–7,580) | 141.8 (0.5–8,423) | |